Osmoprep is owned by Salix Pharms.
Osmoprep contains Sodium Phosphate, Dibasic, Anhydrous; Sodium Phosphate, Monobasic, Monohydrate.
Osmoprep has a total of 1 drug patent out of which 0 drug patents have expired.
Osmoprep was authorised for market use on 16 March, 2006.
Osmoprep is available in tablet;oral dosage forms.
The generics of Osmoprep are possible to be released after 22 June, 2028.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7687075||SALIX PHARMS||Colonic purgative composition with soluble binding agent|| |
(5 years from now)
Drugs and Companies using SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE ingredient
Market Authorisation Date: 16 March, 2006
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic